Ascletis Expands ASC30 Oral GLP-1 Program for Obesity Treatment
Hong Kong, January 26, 2026 — Ascletis Pharma continued progress in the clinical development of ASC30, its investigational oral...
metabolic disease
Advertisement
Junevity Study Reveals Single-Target Control of Cellular Aging
BOSTON, Massachusetts — January 12, 2026 — Junevity has announced the publication of its first peer-reviewed scientific study demonstrating...
Mazdutide 9mg Enters NMPA Review, Advancing Obesity Treatment
BEIJING, China, Nov. 25, 2025 — Innovent Biologics and Eli Lilly announced that the supplementary application for Mazdutide 9mg...
Pfizer Finalizes Metsera Acquisition to Expand Obesity Pipeline
NEW YORK, NY — November 14, 2025 — Pfizer announced it has completed its acquisition of Metsera, Inc., strengthening...
Lilly’s Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 — Eli Lilly and Company (NYSE: LLY) announced positive topline results from two pivotal Phase...
Advertisement
